Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Managing Adverse Effects of Oral vs Injectable ADT in Advanced Prostate Cancer
Managing Adverse Effects of Oral vs Injectable ADT in Advanced Prostate Cancer
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
Risk Assessment in Pulmonary Hypertension: Practice Trends and Updates
Risk Assessment in Pulmonary Hypertension: Practice Trends and Updates
First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer
First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer
Pulmonary Hypertension: Comorbidities With PAH and Group 2 PH
Pulmonary Hypertension: Comorbidities With PAH and Group 2 PH
Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer
Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer
Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors
Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors
Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
Emerging immunotherapy combination strategies in genitourinary malignancies
Emerging immunotherapy combination strategies in genitourinary malignancies
Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer
Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer
